Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malignancies without increased risk of infectious complications

We examined pharmacokinetic-targeted IV busulfan (75–170 mg/m(2), with target AUC of 3500–6000 μmol min) and fludarabine (40 mg/m(2)) × 4 days with rituximab (t-IV Bu/Flu + rituximab) 375 mg/m(2) on days +1 and +8 followed by allogeneic hematopoietic cell transplantation in 19 patients (median age 5...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Hematol
Autori principali: Pidala, Joseph, Roman-Diaz, Jaime, Kim, Jongphil, Nishihori, Taiga, Perkins, Janelle, Tate, Cheryl, Ochoa-Bayona, Jose L., Field, Teresa, Fernandez, Hugo F., Tomblyn, Marcie, Ayala, Ernesto, Anasetti, Claudio, Kharfan-Dabaja, Mohamed A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2011
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5718616/
https://ncbi.nlm.nih.gov/pubmed/21246311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12185-010-0747-x
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi